Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) shares fell 7.5% on Monday . The stock traded as low as $12.24 and last traded at $12.19. 785,504 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 1,506,489 shares. The stock had previously closed at $13.18.
Analysts Set New Price Targets
Several brokerages recently commented on SNDX. HC Wainwright reaffirmed a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Citigroup reduced their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. JPMorgan Chase & Co. upped their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 20th. Scotiabank dropped their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. Finally, StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $36.20.
Read Our Latest Stock Report on SNDX
Syndax Pharmaceuticals Stock Performance
The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -3.43 and a beta of 0.92. The firm has a fifty day moving average price of $14.19 and a 200-day moving average price of $15.73.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million. On average, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.
Insider Transactions at Syndax Pharmaceuticals
In other news, CFO Keith A. Goldan sold 3,777 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the transaction, the chief financial officer now owns 90,746 shares of the company's stock, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company's stock.
Institutional Investors Weigh In On Syndax Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in Syndax Pharmaceuticals in the fourth quarter valued at approximately $26,000. Quantbot Technologies LP acquired a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter valued at $49,000. Virtus ETF Advisers LLC boosted its holdings in shares of Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after acquiring an additional 827 shares in the last quarter. Cape Investment Advisory Inc. boosted its stake in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after purchasing an additional 3,927 shares in the last quarter. Finally, KBC Group NV grew its holdings in Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after acquiring an additional 3,559 shares during the last quarter.
About Syndax Pharmaceuticals
(
Get Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Recommended Stories
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
